Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1;67(6):675-680.
doi: 10.1097/MAT.0000000000001373.

HVAD Usage and Outcomes in the Current Pediatric Ventricular Assist Device Field: An Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Analysis

Scott R Auerbach  1 , Kathleen E Simpson; on Behalf of the Action Learning Network Investigators
Affiliations

HVAD Usage and Outcomes in the Current Pediatric Ventricular Assist Device Field: An Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Analysis

Scott R Auerbach et al. ASAIO J. .

Abstract

Advanced Cardiac Therapies Improving Outcomes Network (ACTION) is the first pediatric ventricular assist device (VAD) quality improvement network (46 centers). We aimed to describe outcomes with the HeartWare HVAD from ACTION centers. Patients with an HVAD implant in the ACTION registry (April 2018-April 2020) were analyzed. Baseline characteristics, adverse events, and survival were described. There were 50 patients implanted with a HVAD during the study period [36 cardiomyopathy, 8 congenital heart disease (CHD), and 6 other] and 21 (42%) had a prior sternotomy. Median age (range) was 12.9 years (3.4-19.1), body surface area was 1.3 m2 (0.56-2.62), and weight was 41.8 kg (12.8-135.3). Most were INTERMACS profile 2 (n = 26, 52%). Mechanical ventilation and ECMO were used pre-HVAD in 13 (26%) and 6 (12%), respectively. Median time on VAD was 71 (5-602) days. Survival was 96% at 1 year; 3 deaths were recorded, all of whom had CHD (p = 0.001). Neither ECMO nor mechanical ventilation were associated with death (p > 0.29). Most frequent AEs were bleeding (n = 7, 14%) and infection (n = 7, 14%). Stroke was rare (n = 2, 4%). ACTION Network HVAD outcomes were excellent, with 96% survival at 1 year and only 4% occurrence of stroke. Major bleeding and infection were the most common adverse events.

PubMed Disclaimer

References

    1. Burstein DS, Shamszad P, Dai D, et al. Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults. Am Heart J. 209: 9–19, 2019.
    1. Nandi D, Lin KY, O’Connor MJ, et al. Hospital charges for pediatric heart failure-related hospitalizations from 2000 to 2009. Pediatr Cardiol. 37: 512–518, 2016.
    1. Hollander SA, Bernstein D, Yeh J, Dao D, Sun HY, Rosenthal D. Outcomes of children following a first hospitalization for dilated cardiomyopathy. Circ Heart Fail. 5: 437–443, 2012.
    1. Fraser CD Jr, Jaquiss RD, Rosenthal DN, et al.; Berlin Heart Study Investigators. Prospective trial of a pediatric ventricular assist device. N Engl J Med. 367: 532–541, 2012.
    1. Blume ED, Rosenthal DN, Rossano JW, et al.; PediMACS Investigators. Outcomes of children implanted with ventricular assist devices in the United States: First analysis of the pediatric interagency registry for mechanical circulatory support (PediMACS). J Heart Lung Transplant. 35: 578–584, 2016.